Oral GLP-1 Receptor Agonists: The Next Generation of Obesity Pharmacotherapy

Abstract

Background Obesity is a chronic, relapsing disease associated with cardiometabolic complications and substantial health-system burden. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed pharmacological weight management, but injectable administration, access, cost, and treatment persistence can limit their use. Oral GLP-1 RAs may expand treatment options by combining incretin-based efficacy with tablet administration.

Objective To review the pharmacology, clinical evidence, therapeutic applications, safety, and future directions of oral GLP-1 receptor agonists for obesity pharmacotherapy.

Methods A narrative review was developed from peer-reviewed clinical trials and reviews, regulatory documents, and authoritative prescribing information. Emphasis was placed on oral semaglutide and orforglipron, including phase 3 evidence available through October 2026. This was not a systematic review and no formal risk-of-bias assessment or quantitative synthesis was performed.

Results In the OASIS 4 randomized trial, oral semaglutide 25 mg daily produced an estimated mean body-weight change of −13.6% at week 64, compared with −2.2% with placebo, among adults with overweight or obesity without diabetes. In the 72-week ATTAIN-1 trial, orforglipron produced mean body-weight changes of −7.5%, −8.4%, and −11.2% at the 6-mg, 12-mg, and 36-mg doses, respectively, compared with −2.1% with placebo. Gastrointestinal adverse events were common with both agents. Oral semaglutide and orforglipron received US approval for chronic weight management in 2025 and 2026, respectively; regulatory status differs by jurisdiction.

Conclusion Oral GLP-1 RAs represent a major advance in obesity treatment, potentially improving convenience and expanding patient choice. Their benefits must be considered alongside gastrointestinal tolerability, contraindications, medication administration requirements, cost, access, and the need for long-term follow-up. Comparative effectiveness should not be inferred from cross-trial weight-loss percentages.

Keywords

Authors & affiliations

Cite this article

Patel Krushi. Oral GLP-1 Receptor Agonists: The Next Generation of Obesity Pharmacotherapy. ClinSphere Journals. 2026;1(1). https://doi.org/10.5281/zenodo.23793510

1. Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707.
2. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023. doi:10.1016/j.jacc.2013.11.004.
3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001.
4. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
5. Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969.